Key result
Insulin-requiring diabetes was associated with higher 1-year target lesion revascularization compared to non-diabetics after bare-metal stenting (11.3% vs 6.3%; P=0.03).
Why the study?
Does bare-metal stenting in low-restenosis-risk lesions yield different clinical outcomes in diabetic patients compared to non-diabetic patients?
Cohort (n=1,951)
No
Does bare-metal stenting in low-restenosis-risk lesions yield different clinical outcomes in diabetic patients compared to non-diabetic patients?
Bare-metal stenting in coronary lesions with low restenosis risk yields similar 1-year outcomes in non-insulin requiring diabetics compared to non-diabetics, but worse outcomes in insulin-requiring diabetics.
Answers are grounded in this paper and cite their sources.
May warrant avoiding bare-metal stents in insulin-requiring diabetes; leaves open confirmation in randomized contemporary cohorts.
OBJECTIVE: To evaluate the clinical results of diabetic patients undergoing percutaneous coronary intervention (PCI) for coronary artery lesions carrying a low risk of restenosis treated with a bare-metal stent (BMS). BACKGROUND: There is a discrepancy between current international guidelines on the use of BMS in diabetics with low risk of restenosis coronary artery lesions. METHODS AND RESULTS: Registry data from diabetic patients who underwent non-urgent PCI in a high-volume tertiary referral hospital in the Netherlands was used. The main outcomes were target lesion revascularization (TLR) and the composite of cardiac death, myocardial infarction, and target vessel revascularization at 1-year of follow-up. A total of 1,951 patients were included, of which 1,596 non-diabetics (non-DM), 231 non-insulin requiring diabetics (NIRDM), and 124 insulin requiring diabetics (IRDM).TLR rates in non-DM versus NIRDM were similar (6.3% vs. 5.6%; P = 0.68), whereas TLR in IRDM was higher (6.3% vs. 11.3%; P = 0.03). The composite of cardiovascular clinical outcomes was not significantly different in non-DM versus NIRDM (9.5% vs. 13.4%; P = 0.07), though in IRDM the incidence was higher (9.5% vs. 17.7%; P < 0.01). CONCLUSION: No differences were observed in TLR or composite clinical endpoint at 1-year between non-DM and NIRDM after BMS placement in coronary artery lesions carrying a low risk of restenosis. The presence of IRDM was associated with higher TLR rates when treated with BMS. These results imply that BMS placement may be considered in patients with NIRDM but further work is required to define treatment strategies and, more importantly, improve the outcomes in diabetics.
No takes yet. Share an insight, caveat, or question.
Woudstra et al. (2012) conducted a cohort in Coronary artery disease with low risk of restenosis (n=1,951). Insulin-requiring diabetes (IRDM) vs. Non-diabetics (non-DM) was evaluated on Target lesion revascularization (TLR) (p=0.03). Insulin-requiring diabetes was associated with higher 1-year target lesion revascularization compared to non-diabetics after bare-metal stenting (11.3% vs 6.3%; P=0.03).
Synapse has enriched 10 related papers. Consider them for comparative context: